Shanghai MicroPort MedBot (Group) Co., Ltd.

上海微创医疗机器人(集团)股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2252)

VOLUNTARY ANNOUNCEMENT IN RESPECT OF THE 510(k) CLEARANCE FOR HONGHU (鸿鹄®) ORTHOPEDIC SURGICAL ROBOT FROM FDA

This announcement is made by Shanghai MicroPort MedBot (Group) Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The board of directors of the Company (the "**Board**") is pleased to announce that the SkyWalker™ Total Knee System (registered name in China of which is Honghu (鸿鹄®)) (the "**Honghu (鸿鹄®)**"), which is independently developed by the Group, has obtained a 510(k) clearance from the U.S. Food and Drug Administration (the "**FDA**"), becoming the first and the only Chinese surgical robot to be cleared by the FDA as of the date of this announcement.

ABOUT HONGHU (鸿鹄®)

Honghu (鸿鹄®) enjoys technical advantages such as precise operation, efficient synergy, safety protection and strong compatibility. Before surgery, its planning system can assist surgeons to formulate personalized prosthesis implantation plans based on patients' preoperative CT scan data and prosthesis model data. During surgery, the precise positioning from surgical planning and the utilisation of registration technology in combination with the self-developed highly dexterous and lightweight robotic arm(s) allow for an osteotomy to be quickly completed, thus helping to improve the accuracy and efficiency of the operation. Honghu (鸿鹄®) avoids the need for positioning of the medullary cavity in traditional surgery. As there is no intramedullary rod implantation during the surgery, Honghu (鸿鹄®) reduces surgical damage and blood loss, improves the postoperative lower limb alignment, reduces surgical complications, and helps patients achieve faster recovery after surgery. Honghu (鸿鹄®) has previously been approved by the National Medical Products Administration of China.

IMPACT ON THE COMPANY

Honghu (鴻鵠®)'s obtaining of clearance from the FDA is a key milestone in the Group's globalization strategy, which is conducive to enhancing the position of China's surgical robots in the international market, and will help the globalization of high-end medical devices "intelligently manufactured in China". Looking ahead, the Company will further strengthen global medical-industrial cooperation and technological innovation, and take innovation and internationalization as the twin engines for future development. The Company aims to accelerate the upgrade of intelligent robot solutions, for the sake of providing patients and physicians in China and abroad with comprehensive intelligent surgical solutions to prolong and reshape lives.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in shares of the Company.

By order of the Board
Shanghai MicroPort MedBot (Group) Co., Ltd.
Mr. Sun Hongbin
Chairman

Shanghai, China, 11 July 2022

As at the date of this announcement, the executive director of the Company is Dr. He Chao, the non-executive directors of the Company are Mr. Sun Hongbin, Mr. Sun Xin and Mr. Chen Chen, and the independent non-executive directors of the Company are Dr. Li Minghua, Mr. Yao Haisong and Mr. Mui Wing Hong.